Drug intelligence / Profile preview

indocyanine green + human serum albumin

Development stage: Preclinical
Lead developer: NOVADAQ Technologies
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous

Overview

Indocyanine green + human serum albumin (ICG-HSA) is a fluorescent imaging agent that combines indocyanine green with human serum albumin to enhance imaging performance during surgical procedures. The complex offers improved water solubility, enhanced photostability, longer blood half-life, reduced aggregation in blood, and superior imaging performance compared to ICG alone. It is primarily used for near-infrared fluorescence-guided surgery (NIRFGS) to accurately localize tumors in real-time, facilitating precise resection.

Brand names: ICG-HSA
Other names: ICG-HSAHSA-ICG

Beyond the preview

Go deeper on indocyanine green + human serum albumin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on indocyanine green + human serum albumin.

Explore the full profile